Consumer & Technology
Research & Informatics
Administration & Shared Services
Board of Directors
Philippe Amouyal, Director
Managing Director of Invus LP
Philippe joined Invus in 1999 as a Managing Director, based in Boston. Prior to joining Invus, Philippe spent 15 years at The Boston Consulting Group in Paris and Boston, where he was a Vice President and Director and coordinated the global electronics and software practice from 1991 on. He holds an M.S. in engineering and a DEA in management from Ecole Centrale de Paris and was a Research Fellow at the Center for Policy Alternatives of the Massachusetts Institute of Technology (MIT). Philippe currently serves as a director for Weight Watchers International (NYSE: WTW), Lexicon Pharmaceuticals (NASDAQ:LXRX), and was previously a director at Unwired Group (ASX: UNW).
Martin Coulter, Director
Martin Coulter was appointed CEO of PatientsLikeMe in 2013 and oversees all of the company’s business operations. He was previously Executive Vice President and General Manager of The Advisory Board Company, a publicly traded healthcare technology and services firm (NASDAQ: ABCO). In that position, he served a range of hospital and healthcare system clients, focusing on establishing best practice performance through data driven technology and consulting programs. Before that, Martin was CEO of Citizens Energy Corporation, a nonprofit healthcare and energy organization. Earlier in his career, he was a principal at the Parthenon Group and a consultant at Bain & Company. Martin holds a master’s degree in business administration from Harvard University, a master of science degree in banking from University College, Dublin, and a bachelor of arts degree in economics from Trinity College, Dublin.
Jamie Heywood, Chairman
Co-Founder and Chairman, PatientsLikeMe
An MIT-trained mechanical engineer, Jamie entered the field of translational medicine when his 29 year old brother Stephen was diagnosed with ALS, or Lou Gehrig's Disease. Jamie co-founded PatientsLikeMe to ensure patient outcomes become the primary driver of the medical care and discovery process. Jamie is also the founder and past CEO of the ALS Therapy Development Institute (ALS TDI), the world's first non-profit biotechnology company. During his tenure at ALS TDI, Jamie helped pioneer an open research model and industrialized therapeutic validation process that made ALS TDI the world's largest and most comprehensive ALS research program. Jamie has founded or co-founded three other health care companies: AOBiome, Genetic Networks, and Love Steve, and is an active member of a community of innovators working to bring dramatic improvements to the way we discover, develop and deliver effective health. Jamie and his brother were the subject of Pulitzer Prize-winning author Jonathan Weiner's biography His Brother’s Keeper, and the documentary So Much So Fast.
Jun Wang, Director
Founder and CEO of iCarbonX
Dr. Wang co-founded Beijing Genomics Institute (BGI) in 1999, which is now widely recognized as one of world’s premier research facilities committed to excellence in genome sciences. During this time, Dr. Wang managed three rounds of fundraising (about 1B$ in total), and acquired a U.S. public company, Complete Genomics. He was recognized with numerous awards and nominations, such as His Royal Highness Prince Foundation, and “Fortune’s 40 under 40” by Fortune Magazine (2013) and “Highly Cited Researchers 2015” by Thomson Reuters. Dr. Wang founded iCarbonX in 2015. He holds a bachelor’s degree in artificial intelligence and a Ph.D. in bioinformatics from Peking University.
Chun Wu, Director
COO of iCarbonX
Dr. Wu joined the Boston Consulting Group (BCG) in 2003. As the global Partner and Managing Director, Dr. Wu led her team to assist multinational and domestic companies to formulate corporate strategy and improve business management. Dr. Wu later joined the Beijing Genomics Institute as the Chief Operating Officer, overseeing manufacturing, marketing and sales globally. Most recently Dr. Wu co-founded and became COO of iCarbonX. Dr. Wu holds a bachelor’s degree in biology from Peking University and a Ph.D. in genetics from Yale University.